ミラバイオロジクス ロゴ

Portfolio

MirAgonist™ Portfolio

Abbreviations: muscle-specific kinase (MuSK), low density lipoprotein receptor-related protein 4 (LRP4), myasthenia gravis (MG), amyotrophic lateral sclerosis (ALS), mesenchymal epithelial transition factor (c-Met), hepatocyte growth factor (HGF), metabolic dysfunction-associated steatohepatitis (MASH) a.k.a. non-alcoholic Steatohepatitis (NASH), Tropomyosin receptor kinase B (TrkB), brain derived neurotrophic factor (BDNF), Alzheimer’s Disease (AD), Parkinson’s Disease (PD)

We can create 1 + 1 = 3
impact together through our partnership!

Portfolio Creation

We will shape our portfolio through a variety of approaches enabled by LassoGraft Technology®, including

“Plug & play” capability: Connect and function immediately

  • Addition of second/third functions to existing antibodies
  • Granting blood-brain barrier (BBB) permeability

Designing molecules considering topology in three dimensions

  • Creation of agonists with controlled 3D conformation

Giving directionality to gene therapy

  • Central Nervous System (CNS)/cell-directed AAV/Lipid Nano Particle (LNP)

Application to modalities other than immunoglobulins

  • Addition of functions to bioactive proteins such as cytokines